← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
51	51 Cellectis CLLS $111M	42	+1	+2%	$167M
52	52 Vericel Corp VCEL $2.12B	40	+1	+3%	$69.3M
53	53 DELISTED NeuBase Therapeutics, Inc. Common Stock NBSE	38	0	0%	$3.34M
54	54 uniQure QURE $1.51B	36	+2	+6%	$73.9M
55	55 Cibus CBUS $101M	35	+35	–	$144M
56	56 Rocket Pharmaceuticals RCKT $257M	35	-16	-31%	$17.9M
57	ATNX 57 DELISTED Athenex, Inc. Common Stock ATNX	33	+17	+106%	$31.1M
58	58 Pluri PLUR $12M	33	+1	+3%	$7.03M
59	59 DELISTED BRAINSTORM CELL THERAPUTC BCLI	32	+6	+23%	$6.72M
60	60 CareDx CDNA $3.45B	27	+4	+17%	$28M
61	61 DELISTED BioLife Solutions BLFS	24	+9	+60%	$7.32M
62	62 ProQR Therapeutics PRQR $206M	23	+5	+28%	$48.9M
63	63 DELISTED Carisma Therapeutics CARM	22	-4	-15%	$1.93M
64	PTE 64 DELISTED PolarityTE, Inc. Common Stock PTE	22	-2	-8%	$14.3M
65	65 Fulgent Genetics FLGT $588M	21	-1	-5%	$11.4M
66	HTGM 66 DELISTED HTG Molecular Diagnostics, Inc. Common Stock HTGM	21	+3	+17%	$3.22M
67	67 Opus Genetics IRD $333M	21	-2	-9%	$4.44M
68	68 Ocugen OCGN $274M	20	-2	-9%	$21.4M
69	ONCS 69 DELISTED OncoSec Medical Incorporated ONCS	20	0	0%	$1.75M
70	70 Capricor Therapeutics CAPR $415M	19	+1	+6%	$3.01M
71	71 Mesoblast MESO $1.8B	18	+2	+13%	$13.6M
72	72 ARK Genomic Revolution ETF ARKG $2.08B	13	+5	+63%	$6.96M
73	73 Krystal Biotech KRYS $9.8B	13	+13	–	$31.3M
74	74 DELISTED DermTech, Inc. Common Stock DMTK	12	+12	–	$62.1M
75	75 Imunon IMNN $5.78M	11	-4	-27%	$956K